Notícias e Atividades da Rein Therapeutics
Presença
Rein Therapeutics é uma empresa listada sob o símbolo ALRN (US).
Fusão, aquisição e financiamento envolvendo Rein Therapeutics.
- O novo nome de Rein Therapeutics é Rein Therapeutics. (publicado em 13 de janeiro de 2025).
- Rein Therapeutics adquiriu Lung Therapeutics (publicado em 1 de novembro de 2023).
Executivos
Veja o organograma con seus 11 executivos principais
Biografias mais buscadas da Rein Therapeutics
- Brian Windsor, Director, President and Chief Executive Officer
- Reinhard Ambros, Director
- Josef Von Rickenbach, Chairman of the Board
Criar um alerta
para seguir os movimentos de executivos da Rein Therapeutics.
Biotecnologia
Rein Therapeutics possui 2.347 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Attovia Therapeutics acaba de anunciar uma arrecadação de fundos de 90 milhões de dólares. (publicado em 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Rein Therapeutics
- Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 ― Aileron
- Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer ― Aileron Therapeutics
- Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference ― Aileron Therapeutics
- Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 ― Aileron Therapeutics
- Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual
- Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference ― Aileron Therapeutics
- View more press releases Close
Redes sociais sobre Rein Therapeutics
- Rein Therapeutics na Wikipedia, Google News e Yahoo Finance
- Rein Therapeutics na LinkedIn, Twitter e YouTube
